Aggregator
What CERN does next matters for science and for international cooperation
Does sharing first authorship on a paper carry a penalty? What the research says
How marathons change runners’ brains: scans point to surprise energy source
Generalizing arene C−H alkylations by radical−radical cross-coupling
Epigenetic editing at individual age-associated CpGs affects the genome-wide epigenetic aging landscape
How to know whether a conference is right for you
Winds on an ultrahot planet challenge climate models
The expanding Universe — do ongoing tensions leave room for new physics?
Paralysed man stands again after receiving ‘reprogrammed’ stem cells
Why Africans should be telling the story of human origins
Shaking up earthquake safety in Nepal with a folk song
RNA function follows form – why is it so hard to predict?
Glaciers are not just blocks of ice — plans to save them mustn’t overlook their hidden life
Reviving the biodiversity around an ancient palace
Curiosity rover detects long-chain carbon molecules on Mars
Fatty acid byproducts could be the remains of microbes—or not
23andMe bankruptcy filing leaves future of genetic data trove uncertain
Direct-to-consumer DNA testing company struggled to profit from drug discovery efforts
Mitophagy in Alzheimer's disease and other metabolic disorders: A focus on mitochondrial-targeted therapeutics
Mitochondria, as central regulators of cellular processes such as energy production, apoptosis, and metabolic homeostasis, are essential to cellular function and health. The maintenance of mitochondrial integrity, especially through mitophagy-the selective removal of impaired mitochondria-is crucial for cellular homeostasis. Dysregulation of mitochondrial function, dynamics, and biogenesis is linked to neurodegenerative and metabolic diseases, notably Alzheimer's disease (AD), which is...
Fluid-based biomarkers for neurodegenerative diseases
Neurodegenerative diseases, such as Alzheimer's Disease (AD), Multiple Sclerosis (MS), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS) are increasingly prevalent as global populations age. Fluid biomarkers, derived from cerebrospinal fluid (CSF), blood, saliva, urine, and exosomes, offer a promising solution for early diagnosis, prognosis, and disease monitoring. These biomarkers can reflect critical pathological processes like amyloid-beta (Aβ) deposition, tau protein...
Advanced biomarkers: Beyond amyloid and tau: Emerging non-traditional biomarkers for alzheimer`s diagnosis and progression
Alzheimer's disease (AD) is the most common neurodegenerative disorder that leads to progressive cognitive decline and imposes a significant socio-economic burden. Traditional diagnostic methods, primarily based on amyloid-beta (Aβ) and tau biomarkers, often identify the disease at late stages, highlighting the need for more sensitive and accessible early detection tools. This review explores emerging non-traditional biomarkers, including salivary, lipid, urinary, synaptic, blood-based, microRNA...
Long-term nucleus basalis cholinergic lesions alter the structure of cortical vasculature, astrocytic density and microglial activity in Wistar rats
Basal forebrain cholinergic neurons (BFCNs) are the sole source of cholinergic innervation to the cerebral cortex and hippocampus in humans and the primary source in rodents. This system undergoes early degeneration in Alzheimer's disease. BFCNs terminal synapses are involved in the regulation of the cerebral blood flow by making classical synaptic contacts with other neurons. Additionally, they are located in proximity to cortical cerebral blood vessels, forming connections with various cell...